Divalent nanobodies to platelet clec-2 can serve as agonists or antagonists

HIGHLIGHTS

• who: Joanne C. Clark from the Institute University of Birmingham, Edgbaston, Birmingham , TT, UK have published the research work: Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists, in the Journal: (JOURNAL) of 27/03/2023
• what: The authors show that (i) a novel divalent nanobody to CLEC-2 LUAS-2 functions as an antagonist to the snake venom toxin rhodocytin in human platelets and low-expressing CLEC-2 DT40 cells and as an agonist in humanised CLEC-2 mouse platelets (which express a higher level of CLEC-2) and __NEWPAGE__ARTICLE Fig . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.